<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394730</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01-ADV</org_study_id>
    <secondary_id>2013 bench to bedside grant</secondary_id>
    <nct_id>NCT02394730</nct_id>
  </id_info>
  <brief_title>Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints</brief_title>
  <acronym>ADVICE</acronym>
  <official_title>A Double Blind Randomised Comparison of Vorapaxar Versus Placebo for the Treatment of HIV Associated Inflammation and Coagulopathy in Patients With Well Controlled HIV Replication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of
      the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer
      expression and markers of cellular immune activation over a period of 12 weeks among people
      with HIV infection who are successfully treated with combination antiretroviral therapy
      containing an HIV integrase inhibitor. A secondary objective of the study will be to
      demonstrate that following cessation of vorapaxar in patients with well controlled HIV
      replication there will be an increase in the levels of d-dimer over a 6 week period. 60
      participants from 4 clinical sites in Australia and the USA will be recruited and followed
      for a minimum of 18 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting participants will be screened and within 14 days randomly allocated to receive
      either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants
      will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the
      week 12 visit, patients will not be dispensed any study treatment. In phase 2 all study
      treatment will stop for 6 weeks. At week 18 patients will be seen for a final study visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences between treatment groups in mean change from baseline log10- d-dimer</measure>
    <time_frame>at week 8 and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each treatment group with plasma HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline in CD4+ cell counts</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline in CD8+ cell counts</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in each treatment group with d-dimer &lt;165ng/mL</measure>
    <time_frame>at week 8 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in each treatment group with d-dimer &gt;165ng/mL</measure>
    <time_frame>at week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline log10 d-dimer</measure>
    <time_frame>at week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline log10 hs-CRP</measure>
    <time_frame>at week 8 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline log10 hs-CRP</measure>
    <time_frame>at week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline log10 IL-6</measure>
    <time_frame>at week 8 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between treatment groups in mean change from baseline log10 IL-6</measure>
    <time_frame>at week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of participants with BARC Type 1, 2, 3, 4, or 5 bleeding episodes</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of participants with any SAE and the cumulative incidence of SAEs</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of participants with any AE and the cumulative incidence of AEs</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in selected serum biochemical parameters including changes in renal function measured by the CKD-EPI estimate of creatinine clearance</measure>
    <time_frame>at week 12 and week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>vorapaxar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5mg of vorapaxar po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorapaxar</intervention_name>
    <description>2.5mg of vorapaxar taken orally once daily for 12 weeks</description>
    <arm_group_label>vorapaxar</arm_group_label>
    <other_name>Zontivity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill taken orally once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive by licensed diagnostic test

          2. aged ≥40 years

          3. plasma HIV RNA &lt;50 copies/mL for at least 24 weeks

          4. screening CD4+ cell count &gt; 50 cells/mm3

          5. treated for at least 12 weeks with a suppressive regimen of combination antiretroviral
             therapy that does not include HIV protease inhibitors and/or NNRTIs (except
             rilpivirine)

          6. plasma d-dimer &gt;200ng/mL (&gt;0.2μg/mL or &gt;0.2mg/L) fibrinogen equivalent units or
             &gt;100ng/mL (&gt;0.1 μg/mL or &gt;0.1mg/L) d-dimer units in the absence of established cause
             (deep vein thrombosis/embolism)

          7. provision of written informed consent

        Exclusion Criteria:

          1. Absolute neutrophil count (ANC) &lt;1000 cells/μL

          2. hemoglobin &lt;10.0 g/dL

          3. platelet count &lt;75,000 cells/μL

          4. AST and/or ALT &gt;2.5 x ULN

          5. estimated glomerular filtration rate &lt;30mL/min/1.73m2 ) using CKD-EPI (Chronic Kidney
             Disease Epidemiology Collaboration) equation

          6. history of myocardial infarction or unstable atherosclerotic disease

          7. history of ischemic stroke or transient ischaemic attack (TIA)

          8. active peptic/duodenal ulcer or other bleeding disorder within the previous 12 months

          9. intent to have surgery within the 6 month period after randomisation

         10. current use of aspirin or P2Y12 antiplatelet therapy

         11. use of anticoagulants, (eg. heparin or warfarin), fibrinolytic therapy, chronic use
             (more than 5 consecutive days) of nonsteroidal anti-inflammatory drugs (NSAIDS),
             strong CYP3A4 inhibitors or inducers. See Manual of Operations for full list of
             medications to avoid.

         12. participants unlikely to be able to remain in follow-up

         13. pregnant or nursing mothers

         14. in the clinical judgement of the investigator, participation in this trial is deemed
             inappropriate as this may conflict with the well-being of the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Emery</last_name>
    <role>Study Director</role>
    <affiliation>University of NSW, Kirby Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Hough, BAppSc</last_name>
    <phone>+61 2 93850900</phone>
    <phone_ext>0897</phone_ext>
    <email>shough@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Georgetown</city>
        <state>Maryland</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Princy Kumar, MD</last_name>
      <phone>202-444-0086</phone>
      <email>kumarp@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Centre</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Baker, MD</last_name>
      <phone>612-873-6876</phone>
      <email>baker@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle McDonald</last_name>
      <phone>+61283824978</phone>
      <email>Kyle.mcdonald@svha.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Finlayson, MD</last_name>
      <phone>+61 2 9331 6151</phone>
      <email>robfin@tspc.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Centre</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Silvers</last_name>
      <phone>+61393416262</phone>
      <email>ResearchUnit@mshc.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Woolley, MD</last_name>
      <phone>+61 3 9594-4564</phone>
      <email>ian.woolley@med.monash.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Clinic</name>
      <address>
        <city>North Fitzroy</city>
        <state>Victoria</state>
        <zip>3068</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Moore, MD</last_name>
      <phone>+61 39485 7700</phone>
      <email>trials@northsideclinic.net.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prahran Market Clinic</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Roth, MD</last_name>
      <phone>+613 9514 0888</phone>
      <email>norm@prahranmarketclinic.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, d-dimer, hs-CRP, activated T-lymphocytes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

